

# Han Zeng

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10081216/publications.pdf>

Version: 2024-02-01

28  
papers

723  
citations

1040056

9  
h-index

752698

20  
g-index

28  
all docs

28  
docs citations

28  
times ranked

629  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion. <i>European Urology</i> , 2019, 75, 752-763.	1.9	123
2	Intratumoral CXCL13 <sup>+</sup> CD8 <sup>+</sup> T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma. , 2021, 9, e001823.		87
3	Intratumoral TIGIT <sup>+</sup> CD8 <sup>+</sup> T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer. , 2020, 8, e000978.		81
4	Tumor-infiltrating CD39 <sup>+</sup> CD8 <sup>+</sup> T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1565-1576.	4.2	72
5	Blockade of DC-SIGN <sup>+</sup> Tumor-Associated Macrophages Reactivates Antitumor Immunity and Improves Immunotherapy in Muscle-Invasive Bladder Cancer. <i>Cancer Research</i> , 2020, 80, 1707-1719.	0.9	61
6	CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1855-1867.	4.2	35
7	Identification and validation of dichotomous immune subtypes based on intratumoral immune cells infiltration in clear cell renal cell carcinoma patients. , 2020, 8, e000447.		35
8	Stromal LAG-3 <sup>+</sup> cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture. , 2020, 8, e000651.		29
9	Immunosuppressive tumor-associated macrophages expressing interleukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer. , 2022, 10, e003416.		28
10	Tumor-infiltrating TNFRSF9 <sup>+</sup> CD8 <sup>+</sup> T cells define different subsets of clear cell renal cell carcinoma with prognosis and immunotherapeutic response. <i>Oncolmmunology</i> , 2020, 9, 1838141.	4.6	23
11	Intratumoral IL22 <sup>+</sup> producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses. <i>International Journal of Cancer</i> , 2020, 146, 542-552.	5.1	22
12	Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1497-1506.	4.2	20
13	CD103 <sup>+</sup> CD8 <sup>+</sup> tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer. <i>British Journal of Cancer</i> , 2022, 126, 1581-1588.	6.4	16
14	CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma. , 2020, 8, e000228.		15
15	Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin <sup>+</sup> cell abundance. <i>Oncolmmunology</i> , 2020, 9, 1747333.	4.6	13
16	PAK1 expression determines poor prognosis and immune evasion in metastatic renal cell carcinoma patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 293-304.	1.6	10
17	Poor clinical outcomes and immunoevasive contexture in interleukin-9 abundant muscle-invasive bladder cancer. <i>International Journal of Cancer</i> , 2020, 147, 3539-3549.	5.1	8
18	Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5 <sup>+</sup> CD8 <sup>+</sup> T cell abundance. <i>Oncolmmunology</i> , 2020, 9, 1810489.	4.6	7

#	ARTICLE	IF	CITATIONS
19	TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer. <i>British Journal of Cancer</i> , 2022, 126, 1310-1317.	6.4	7
20	Tumor-infiltrating IL-17A <sup>+</sup> cells determine favorable prognosis and adjuvant chemotherapeutic response in muscle-invasive bladder cancer. <i>Oncolimmunology</i> , 2020, 9, 1747332.	4.6	6
21	Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 166.e15-166.e25.	1.6	6
22	NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer. , 2022, 10, e004569.		5
23	Intratumoral CCR5 <sup>+</sup> neutrophils identify immunogenic subtype muscle-invasive bladder cancer with favorable prognosis and therapeutic responses. <i>Oncolimmunology</i> , 2020, 9, 1802176.	4.6	4
24	Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	4
25	Poor clinical outcomes and immunoevasive contexture in SIRP <sup>+</sup> tumor-associated macrophages enriched muscle-invasive bladder cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 109.e11-109.e20.	1.6	3
26	Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	4.2	2
27	Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2117-2126.	4.2	1
28	ASO Visual Abstract: Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients. <i>Annals of Surgical Oncology</i> , 2022, 29, 2504-2504.	1.5	0